Searched for
IMMUNO ONCOLOGY DRUG
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Zydus Lifesciences launches world's first nivolumab biosimilar in India, boosting cancer treatment affordabilityAhmedabad-based Zydus Lifesciences has launched Tishtha, the world's first biosimilar of the oncology drug nivolumab, in India. This move s...
- Zydus launches biosimilar for treatment of multiple cancersZydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha wi...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...
- Dr Reddy's launches novel cancer therapy Toripalimab in IndiaDr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma ...
- Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinomaDr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (N...
- Seeking technology, manufacturing partnership with Indian pharma companies, says Mexico foreign secretaryThe Mexican government has partnered with ImmunoAct, an IIT Bombay-incubated company which is developing cutting-edge chimeric antigen rece...
- Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patientsThe Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...
- Bugworks Research bags $18 million in funding round led by Lightrock India, othersBugworks Research said it will continue to invest in its proprietary drug discovery platforms GYROX (for AMR) and DARE (for Immuno-oncology...
- Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 milli...
- Zumutor Biologics gets $4 million in fresh fundsThe company said the capital will be used for the process of new drug filing of its lead molecule (ZM 008) in India, and to go through the ...
- Glenmark Pharma begins clinical trial of anti-myeloma drugThe additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity, it added.
- Glenmark anti-myeloma drug gets clinical trial nod from USFDAThis is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.
- Boehringer Ingelheim not for immuno therapy drugsA patient of a recently introduced immuno therapy drug is former US President Jimmy Carter who was treated with the drug Keytruda of Merck ...
- Global pharma growth to remain steady despite cost pressures: Moody'sCompanies like Bristol Myers Squibb, Merck &Co who have launched the new class cancer drugs in the area of immuno-oncology are expected to ...
- Merck KGaA bets on cancer drugs to revitalise German firmMerck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, ...
- Zenotech to invest over Rs 90 cr in R&DGeneric biopharmaceutical company Zenotech Laboratories is set to invest over Rs 90 crore to strengthen its R&D pipeline.
- Zenotech plans to invest over Rs 90 crore in R&DHyderabad-based generic biopharmaceutical company Zenotech Laboratories is set to invest over Rs 90 crore to strengthen its R&D pipeline.
Load More
